Arecor creates clinically derisked therapeutics for high‑value markets such as diabetes and cardiometabolic diseases using its proprietary Arestat® formulation and drug‑delivery platform. The company collaborates with pharmaceutical and med‑tech partners to develop therapies with superior efficacy and safety profiles, leveraging its validated technology to address unmet patient needs.
Funding
$44.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Developing new therapeutics for diabetes and other cardiometabolic diseases often requires extensive formulation work and clinical testing, which can delay market entry and increase costs. Existing drug‑delivery formats may also have limitations in stability, convenience, or pharmacokinetic performance, reducing patient adherence and therapeutic effectiveness.
Solution
Arecor leverages its proprietary Arestat® formulation and drug‑delivery platform to create clinically de‑risked therapeutics with enhanced stability, convenience, and pharmacokinetic profiles. The technology can convert biologics, peptides, vaccines, and future modalities such as mRNA or cell therapies into formats that are more stable (e.g., cold‑chain independent liquids), easier to administer (e.g., ready‑to‑use liquids, high‑concentration subcutaneous solutions), and provide controlled absorption for improved efficacy. By partnering with pharmaceutical and med‑tech companies, Arecor integrates this platform into partner pipelines, accelerating development timelines and delivering superior product profiles to high‑value markets.
Target Audience
Primary customers are pharmaceutical and medical‑technology companies seeking to enhance the formulation, stability, and delivery of their cardiometabolic and other high‑value therapeutics.
Features
- Proprietary Arestat® formulation technology that improves product stability, enabling cold‑chain‑free liquid formulations.
- Ability to transform lyophilised powders into ready‑to‑use liquids, simplifying reconstitution and administration.
- Development of high‑concentration subcutaneous products with low viscosity and reduced aggregation risk.
- Creation of ready‑to‑administer (RTA) intravenous concentrates and pre‑mixed IV bags for streamlined clinical use.
- Controlled subcutaneous absorption to optimize pharmacokinetic/pharmacodynamic profiles.
- Broad applicability across biologics, biosimilars, novel peptides, vaccines, and emerging modalities such as mRNA and cell/gene therapies.
- Robust IP portfolio protecting the formulation and delivery technology.